(VELA) Study of BLU-222 in Advanced Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05252416 |
Recruitment Status :
Recruiting
First Posted : February 23, 2022
Last Update Posted : April 23, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Advanced Solid Tumors HR+ Breast Cancer CCNE1 Amplification HER2-negative Breast Cancer Ovarian Cancer Endometrial Cancer Gastric Cancer Esophageal Adenocarcinoma Carcinosarcoma | Drug: BLU-222 Drug: Carboplatin Drug: Ribociclib Drug: Fulvestrant | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 366 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors |
Actual Study Start Date : | April 7, 2022 |
Estimated Primary Completion Date : | November 30, 2025 |
Estimated Study Completion Date : | September 30, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: BLU-222 Monotherapy
Dose Escalation: Multiple doses for BLU-222 for oral administration Dose Expansion: Oral dose of BLU-222 as determined during Dose Escalation
|
Drug: BLU-222
Oral administration |
Experimental: BLU-222 + Carboplatin
Dose Escalation: Multiple doses for BLU-222 for oral administration at doses deemed appropriate based on BLU-222 Monotherapy arm and multiple doses of Carboplatin at the approved dose. Dose Expansion: Oral dose of BLU-222 as determined during Dose Escalation and Carboplatin IV infusion at approved dose |
Drug: BLU-222
Oral administration Drug: Carboplatin IV Infusion |
Experimental: BLU-222 + Ribociclib + Fulvestrant
Dose Escalation: Multiple doses for BLU-222 for oral administration at doses deemed appropriate based on BLU-222 Monotherapy arm along with Ribociclib and Fulvestrant at the approved doses. Dose Expansion: Oral dose of BLU-222 as determined during dose escalation and approved doses of Ribociclib and Fulvestrant |
Drug: BLU-222
Oral administration Drug: Ribociclib Oral administration Drug: Fulvestrant Intra muscular administration |
Experimental: BLU-222 + Fulvestrant
Dose Expansion: Oral dose of BLU-222 as determined during Dose Escalation + fulvestrant at the approved dose
|
Drug: BLU-222
Oral administration Drug: Fulvestrant Intra muscular administration |
- [Phase 1] Determine the maximum tolerated dose (MTD) of BLU-222 [ Time Frame: Approximately 21 months ]
- [Phase 1] Determine the recommended Phase 2 dose (RP2D) of BLU-222 [ Time Frame: Approximately 21 months ]
- [Phase 1] Rate and severity of adverse events [ Time Frame: Approximately 21 months ]
- [Phase 2] Overall response rate (ORR) [ Time Frame: Approximately 43 months ]
- [Phase 2] Rate and severity of adverse events [ Time Frame: Approximately 43 months ]
- [Phase 1] Overall response rate (ORR) [ Time Frame: Approximately 21 months ]
- [Phase 1] Time of last quantifiable plasma drug concentration (Tlast) [ Time Frame: Approximately 21 months ]
- [Phase 1] Area under the plasma concentration time curve from time 0 to 12 hours (AUC0-12) [ Time Frame: Approximately 21 months ]
- [Phase 1] Area under the plasma concentration time curve from time 0 to 24 hours (AUC0-24) [ Time Frame: Approximately 21 months ]
- [Phase 1] Trough concentration (Ctrough) [ Time Frame: Approximately 21 months ]
- [Phase 1] Apparent volume of distribution (Vz/F) [ Time Frame: Approximately 21 months ]
- [Phase 1] Terminal elimination half-life (t½) [ Time Frame: Approximately 21 months ]
- [Phase 1] Apparent oral clearance(CL/F) [ Time Frame: Approximately 21 months ]
- [Phase 1] Accumulation ratio (R) [ Time Frame: Approximately 21 months ]
- [Phase 1] To assess treatment-induced modulation of biomarkers [ Time Frame: Approximately 21 months ]
- [Phase 1 and Phase 2] Duration of Response (DOR) [ Time Frame: Approximately 43 months ]
- [Phase 1 and Phase 2] Disease control rate (DCR) [ Time Frame: Approximately 43 months ]
- [Phase 1 and Phase 2] Clinical benefit rate (CBR) [ Time Frame: Approximately 43 months ]
- [Phase 1 and Phase 2] Progression free survival (PFS) [ Time Frame: Approximately 43 months ]
- [Phase 1 and Phase 2] Change in CA-125 levels [ Time Frame: Approximately 43 months ]
- [Phase 1 and Phase 2] Maximum plasma drug concentration (Cmax) [ Time Frame: Approximately 43 months ]
- [Phase 1 and Phase 2] Time to maximum plasma drug concentration (Tmax) [ Time Frame: Approximately 43 months ]
- [Phase 1 and Phase 2] Last measurable concentration (Clast) [ Time Frame: Approximately 43 months ]
- [Phase 1 and Phase 2] Area under the concentration-time curve from time 0 to the time of the last measured concentration AUC(0-last) [ Time Frame: Approximately 43 months ]
- [Phase 2] Overall survival (OS) [ Time Frame: Approximately 43 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Advanced solid tumors that has progressed beyond standard of care OR
- HR+ HER2- BC that has progressed following treatment with a CDK4/6 inhibitor OR
- Endometrial and gastric cancer that has progressed after at least 2 prior therapies (including one prior platinum therapy) OR
- Platinum refractory or platinum resistant ovarian cancer CCNE1 amplified tumors that have progressed beyond standard of care
Exclusion Criteria:
- Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis.
-
Have received the following anticancer therapy:
a. Previous therapy with CDK2i, PKMYT1i, or WEE1i, except in Part 1A where up to 10 patients who previously received PKMYT1i, or WEE1 inhibitor will be permitted.
- Have central nervous system (CNS) metastases or spinal cord compression that is associated with progressive neurological symptoms or requires increasing doses of corticosteroids to control the CNS disease.
- Have known intracranial hemorrhage and/or bleeding diatheses.
- Have clinically active ongoing ILD of any etiology, including drug-induced ILD, and radiation pneumonitis within 28 days prior to initiation of study treatment.
- Have any unresolved toxicities from prior therapy greater than CTCAE Grade 1 or that have not resolved to baseline at the time of starting the study.
- Have mean resting QTcF > 450 msec in men or QTcF > 470 msec in women, a history of prolonged QT syndrome or Torsades de pointes, or a familial history of prolonged QT syndrome.
- Have clinically significant, uncontrolled, cardiovascular disease including congestive heart failure Grade III or IV according to the New York Heart Association classification; myocardial infarction or unstable angina within the previous 6 months, uncontrolled hypertension, or clinically significant, uncontrolled arrhythmias, including bradyarrhythmia that may cause QT prolongation (eg, Type II second degree heart block or third-degree heart block).
- Have a history of another primary malignancy other than completely resected carcinomas in situ) that has been diagnosed or required therapy within 2 years prior to initiation of study treatment.
- Have known active, uncontrolled infection (viral, bacterial, or fungal), including tuberculosis, hepatitis B virus (HBV), hepatitis C virus, AIDS-related illness, or COVID-19 infection (symptoms and a positive test result).
- Requires treatment with a prohibited medication or herbal remedy that cannot be discontinued at least 2 weeks before the start of study drug administration.
- Have planned major surgical procedure within 14 days of the first dose of study drug (procedures such as central venous catheter placement, tumor needle biopsy, and feeding tube placement are not considered major surgical procedures).
- Unwilling or unable to comply with scheduled visits, study drug administration plan, laboratory tests, or other study procedures and study restrictions.
- Patient is a woman who is not postmenopausal or surgically sterile, and is unwilling to abstain from sexual intercourse or employ highly effective contraception OR is a man who is not surgically sterile, and is unwilling to abstain from sexual intercourse or employ highly effective contraception
- Patient is a pregnant female
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05252416
Contact: Blueprint Medicines | 617-714-6707 | medinfo@blueprintmedicines.com |
Responsible Party: | Blueprint Medicines Corporation |
ClinicalTrials.gov Identifier: | NCT05252416 |
Other Study ID Numbers: |
BLU-222-1101 |
First Posted: | February 23, 2022 Key Record Dates |
Last Update Posted: | April 23, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
CDK2 CCNE1 Platinum-resistance Platinum-refractory CDK4/6i |
Ribociclib Carboplatin Fulvestrant ER+ Breast Cancer |
Breast Neoplasms Endometrial Neoplasms Carcinosarcoma Mixed Tumor, Mullerian Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Neoplasms by Histologic Type Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Neoplasms, Female Urogenital Neoplasms |
Genital Diseases Uterine Neoplasms Uterine Diseases Neoplasms, Complex and Mixed Sarcoma Neoplasms, Connective and Soft Tissue Carboplatin Fulvestrant Antineoplastic Agents Antineoplastic Agents, Hormonal Estrogen Receptor Antagonists Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |